Literature DB >> 9619864

Effect of liposomalization on the antitumor activity, side-effects and tissue distribution of CPT-11.

Y Sadzuka1, S Hirotsu, S Hirota.   

Abstract

We have examined the efficacy of liposomalization and polyethyleneglycol (PEG) modification of liposomes on the antitumor activity, side-effects and tissue distribution of irinotecan hydrochloride (CPT-11). PEG-liposome was confirmed to elevate the plasma circulation of CPT-11 and SN-38 (active metabolite) concentrations. The tumor accumulation of CPT-11 and SN-38 was increased by the PEG-modified liposomes. The antitumor activity of CPT-11 increased due to the elevated tumor distribution of CPT-11 and SN-38 levels by the PEG-modified liposomes. In the tumor, CPT-11 was converted to SN-38. Thus, it is considered that passive targeting to the tumor by liposomalization elevated the SN-38 level in the tumor especially and increased the antitumor activity of CPT-11. Furthermore, intestinal disorder, a side toxicity of CPT-11, decreased dependent on the CPT-11 and SN-38 concentrations in the bile by liposomalization. Although the liposomes induce improved tissue distribution of the prodrug, the tissue distribution of active metabolites does not always improve. However, CPT-11-entrapped liposome was useful, as CPT-11 is converted to SN-38 in the tumor. These results suggested that the usefulness of CPT-11 could be extended.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9619864     DOI: 10.1016/s0304-3835(98)00031-7

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  9 in total

1.  A phase I study of liposomal-encapsulated docetaxel (LE-DT) in patients with advanced solid tumor malignancies.

Authors:  John F Deeken; Rebecca Slack; Glen J Weiss; Ramesh K Ramanathan; Michael J Pishvaian; Jimmy Hwang; Karen Lewandowski; Deepa Subramaniam; Aiwu Ruth He; Ion Cotarla; Aquilur Rahman; John L Marshall
Journal:  Cancer Chemother Pharmacol       Date:  2012-12-30       Impact factor: 3.333

Review 2.  Nanoparticle-Based Therapeutics for Brain Injury.

Authors:  Vimala N Bharadwaj; Duong T Nguyen; Vikram D Kodibagkar; Sarah E Stabenfeldt
Journal:  Adv Healthc Mater       Date:  2017-10-16       Impact factor: 9.933

Review 3.  Factors controlling the pharmacokinetics, biodistribution and intratumoral penetration of nanoparticles.

Authors:  Mark J Ernsting; Mami Murakami; Aniruddha Roy; Shyh-Dar Li
Journal:  J Control Release       Date:  2013-09-25       Impact factor: 9.776

4.  Treatment of visceral leishmaniasis with sterically stabilized liposomes containing camptothecin.

Authors:  M E Proulx; A Désormeaux; J F Marquis; M Olivier; M G Bergeron
Journal:  Antimicrob Agents Chemother       Date:  2001-09       Impact factor: 5.191

5.  Preparation of irinotecan-loaded folate-targeted liposome for tumor targeting delivery and its antitumor activity.

Authors:  Ziqiang Zhang; Jing Yao
Journal:  AAPS PharmSciTech       Date:  2012-05-26       Impact factor: 3.246

Review 6.  Cancer nanomedicines: so many papers and so few drugs!

Authors:  Vincent J Venditto; Francis C Szoka
Journal:  Adv Drug Deliv Rev       Date:  2012-10-01       Impact factor: 15.470

7.  Irinotecan Delivery by Lipid-Coated Mesoporous Silica Nanoparticles Shows Improved Efficacy and Safety over Liposomes for Pancreatic Cancer.

Authors:  Xiangsheng Liu; Allen Situ; Yanan Kang; Katie Rose Villabroza; Yupei Liao; Chong Hyun Chang; Timothy Donahue; Andre E Nel; Huan Meng
Journal:  ACS Nano       Date:  2016-02-09       Impact factor: 15.881

8.  The novel highly lipophilic topoisomerase I inhibitor DB67 is effective in the treatment of liver metastases of murine CT-26 colon carcinoma.

Authors:  Lluis A Lopez-Barcons; Junhong Zhang; Gunching Siriwitayawan; Thomas G Burke; Roman Perez-Soler
Journal:  Neoplasia       Date:  2004 Sep-Oct       Impact factor: 5.715

9.  Effective irinotecan (CPT-11)-containing liposomes: intraliposomal conversion to the active metabolite SN-38.

Authors:  Y Sadzuka; S Hirotsu; S Hirota
Journal:  Jpn J Cancer Res       Date:  1999-02
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.